Logo image of ANIX

ANIXA BIOSCIENCES INC (ANIX) Stock Fundamental Analysis

NASDAQ:ANIX - Nasdaq - US03528H1095 - Common Stock - Currency: USD

3.49  +0.11 (+3.25%)

Premarket: 3.63 +0.14 (+4.01%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ANIX. ANIX was compared to 558 industry peers in the Biotechnology industry. ANIX has a great financial health rating, but its profitability evaluates not so good. ANIX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ANIX has reported negative net income.
In the past year ANIX has reported a negative cash flow from operations.
In the past 5 years ANIX always reported negative net income.
In the past 5 years ANIX always reported negative operating cash flow.
ANIX Yearly Net Income VS EBIT VS OCF VS FCFANIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -71.47%, ANIX is doing worse than 64.70% of the companies in the same industry.
ANIX's Return On Equity of -75.52% is in line compared to the rest of the industry. ANIX outperforms 52.69% of its industry peers.
Industry RankSector Rank
ROA -71.47%
ROE -75.52%
ROIC N/A
ROA(3y)-47.1%
ROA(5y)-56.61%
ROE(3y)-49.97%
ROE(5y)-60.17%
ROIC(3y)N/A
ROIC(5y)N/A
ANIX Yearly ROA, ROE, ROICANIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANIX Yearly Profit, Operating, Gross MarginsANIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ANIX has been increased compared to 1 year ago.
The number of shares outstanding for ANIX has been increased compared to 5 years ago.
There is no outstanding debt for ANIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANIX Yearly Shares OutstandingANIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ANIX Yearly Total Debt VS Total AssetsANIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 52.33 indicates that ANIX is not in any danger for bankruptcy at the moment.
ANIX's Altman-Z score of 52.33 is amongst the best of the industry. ANIX outperforms 98.39% of its industry peers.
There is no outstanding debt for ANIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 52.33
ROIC/WACCN/A
WACCN/A
ANIX Yearly LT Debt VS Equity VS FCFANIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 8.89 indicates that ANIX has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.89, ANIX is doing good in the industry, outperforming 73.66% of the companies in the same industry.
ANIX has a Quick Ratio of 8.89. This indicates that ANIX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.89, ANIX is in the better half of the industry, outperforming 73.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.89
Quick Ratio 8.89
ANIX Yearly Current Assets VS Current LiabilitesANIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

ANIX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.70%.
Looking at the last year, ANIX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-2.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ANIX will show a very strong growth in Earnings Per Share. The EPS will grow by 33.88% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.31%
EPS Next 2Y-3.55%
EPS Next 3Y-4.79%
EPS Next 5Y33.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANIX Yearly Revenue VS EstimatesANIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2023 2029 2030 2031 2032 200M 400M 600M
ANIX Yearly EPS VS EstimatesANIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIX Price Earnings VS Forward Price EarningsANIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANIX Per share dataANIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

ANIX's earnings are expected to decrease with -4.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.55%
EPS Next 3Y-4.79%

More info and screens

0

5. Dividend

5.1 Amount

ANIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANIXA BIOSCIENCES INC

NASDAQ:ANIX (6/23/2025, 8:00:00 PM)

Premarket: 3.63 +0.14 (+4.01%)

3.49

+0.11 (+3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-28 2025-05-28/amc
Earnings (Next)09-04 2025-09-04/amc
Inst Owners15.68%
Inst Owner Change-4.75%
Ins Owners2.42%
Ins Owner Change5%
Market Cap112.38M
Analysts82.22
Price Target9.18 (163.04%)
Short Float %1.14%
Short Ratio3.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.86%
Min EPS beat(2)1.96%
Max EPS beat(2)11.76%
EPS beat(4)2
Avg EPS beat(4)1.68%
Min EPS beat(4)-3.81%
Max EPS beat(4)11.76%
EPS beat(8)5
Avg EPS beat(8)2.93%
EPS beat(12)8
Avg EPS beat(12)11.66%
EPS beat(16)10
Avg EPS beat(16)2.39%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-8.72%
EPS NY rev (3m)-16.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.99
P/tB 6.99
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.47%
ROE -75.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.1%
ROA(5y)-56.61%
ROE(3y)-49.97%
ROE(5y)-60.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.89
Quick Ratio 8.89
Altman-Z 52.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y-3.31%
EPS Next 2Y-3.55%
EPS Next 3Y-4.79%
EPS Next 5Y33.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.77%
OCF growth 3YN/A
OCF growth 5YN/A